- Home
- BRT vs CTNM Comparison
BRT vs CTNM Comparison
Compare BRT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRT | CTNM |
|---|---|---|
| Founded | 1972 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.3M | 507.0M |
| IPO Year | 1994 | 2024 |
Fundamental Metrics
Financial Performance| Metric | BRT | CTNM |
|---|---|---|
| Price | $14.12 | $13.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $19.75 | ★ $19.80 |
| AVG Volume (30 Days) | 23.4K | ★ 180.4K |
| Earning Date | 06-24-2026 | 06-08-2026 |
| Dividend Yield | ★ 6.93% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $14.00 | $3.35 |
| 52 Week High | $18.50 | $16.33 |
Technical Indicators
Market Signals| Indicator | BRT | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 35.93 | 41.59 |
| Support Level | N/A | $10.39 |
| Resistance Level | $15.11 | $13.18 |
| Average True Range (ATR) | 0.32 | 1.12 |
| MACD | -0.06 | -0.28 |
| Stochastic Oscillator | 0.00 | 1.78 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.